Kennedy Hastalığı ve Amyotrofik Lateral Sklerozda (ALS) Hücre Sinyalleşmesi, Reinnervasyon ve Metabolizma

This clinical trial investigates the role of insulin signaling pathways and metabolic profiles in maintaining collateral reinnervation and muscle function in ALSALSAmyotrofik Lateral Skleroz, motor nöronların ilerleyici dejenerasyonu ile karakterize nörodejeneratif bir hastalıktır. patients. The study aims to correlate whole-body and skeletal muscle metabolic profiles with the extent of collateral reinnervation, motor function, and motor neuron loss. The research will involve clinical and electrophysiological assessments, body composition analysis, insulin secretion and resistance measurements, IGF-1 axis component quantification, and muscle biopsies for morphological analysis and quantification of innervation. The study will compare data from 20 ALSALSAmyotrofik Lateral Skleroz, motor nöronların ilerleyici dejenerasyonu ile karakterize nörodejeneratif bir hastalıktır. patients with those of 10 healthy controls and 10 patients with spinal and bulbar muscular atrophy. The findings will identify potential therapeutic targets for promoting compensatory reinnervation and slowing disease progression in ALSALSAmyotrofik Lateral Skleroz, motor nöronların ilerleyici dejenerasyonu ile karakterize nörodejeneratif bir hastalıktır..

Önemli Takib Edilecek Noktalar:
- The study aims to elucidate the role of insulin signaling and metabolic profiles in maintaining collateral reinnervation and muscle function in ALSALSAmyotrofik Lateral Skleroz, motor nöronların ilerleyici dejenerasyonu ile karakterize nörodejeneratif bir hastalıktır..
- The research will correlate metabolic profiles with clinical and electrophysiological data, innervation quantification, and IGF-1 axis components.
- The findings may identify novel therapeutic targets for promoting compensatory reinnervation and slowing disease progression in ALSALSAmyotrofik Lateral Skleroz, motor nöronların ilerleyici dejenerasyonu ile karakterize nörodejeneratif bir hastalıktır., potentially benefiting other neuromuscular disorders.